Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century

  • Ruth Duncan
  • Francesco M. Veronese
Part of the Milestones in Drug Therapy book series (MDT)


The collected Chapters in this volume describe the current status of poly(ethylene glycol) (PEG) modification of proteins, peptides, oligonucleotides and small molecule drugs, the recent advances in conjugation chemistry, and new clinical products. The book provides an excellent update in this rapidly evolving field, and the comprehensive collection of Chapters complements well past reviews/volumes that have documented the evolution of PEGylation. For example, a reader new to this field is encouraged to gain the historical perspective by reading the following reviews [1, 2, 3, 4, 5, 6, 7, 8]. Only then is it possible to see just how far this field has come and understand that it has already established a new class of therapeutics as we start the 21st Century!


Conjugation Chemistry Macromolecular Drug High Molecular Weight PEGs Macromolecular Prodrug Polymer Therapeutics 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fuertges F, Abuchowski A (1990) The clinical efficacy of poly(ethyleneglycol)-modified proteins. J Controlled Rel 11: 139–148CrossRefGoogle Scholar
  2. 2.
    Nucci ML, Shorr R, Abuchowski A (1991) The therapeutic values of poly(ethylene glycol)-mod-ified proteins. Adv Drug Delivery Rev 6: 133–151CrossRefGoogle Scholar
  3. 3.
    Francis GE, Delgado C, Fisher D, Malik F, Argrawl AK (1996) Polyethylene glycol modification: Relevance to improved methodology to tumour targeting. J Drug Targeting 3: 321–340CrossRefGoogle Scholar
  4. 4.
    Davis FF (2002) The origin of pegnology. Adv Drug Del Rev 54: 457–458CrossRefGoogle Scholar
  5. 5.
    Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nature Rev Drug Discov 2: 214–221CrossRefGoogle Scholar
  6. 6.
    Veronese FM, Harris JM (Eds) (2002) Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 54: 453–609Google Scholar
  7. 7.
    Harris JM, Veronese FM (Eds) Pegylation of peptides and proteins II — Clinical Evaluation. Adv Drug Deliv Rev 55: 1261–1277Google Scholar
  8. 8.
    Veronese FM, Harris JM (Eds) (2008) Pegylation of peptides and proteins III: Advances in chemistry and clinical applications. Adv Drug Deliv Rev 60: 1–87Google Scholar
  9. 9.
    Duncan R (2005) Targeting and intracellular delivery of drugs. In: RA Meyers (ed.): Encyclopedia of Molecular Cell Biology and Molecular Medicine. Wiley-VCH Verlag, GmbH & Co. KGaA, Weinheim, Germany, 163–204Google Scholar
  10. 10.
    Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nature Rev Drug Discov 2: 750–763CrossRefGoogle Scholar
  11. 11.
    Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discov 4: 145–160CrossRefGoogle Scholar
  12. 12.
    Couvreur P, Vauthier C (2006) Nanotechnology: Intelligent design to treat complex disease. Pharm Res 23:1417–1450CrossRefPubMedGoogle Scholar
  13. 13.
    Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347–360CrossRefPubMedGoogle Scholar
  14. 14.
    Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688–701CrossRefPubMedGoogle Scholar
  15. 15.
    US Food and Drug Administration accessed at drugsatfda/Google Scholar
  16. 16.
    Ferrari M (2005) Cancer nanotechnology: Opportunities and challenges. Nature Rev Cancer 5: 161–171CrossRefGoogle Scholar
  17. 17.
    European Science Foundation Forward Look on Nanomedicine (2005) http://www.esf.orgGoogle Scholar
  18. 18.
    Ringsdorf H (2004) Hermann Staudingerand the Future of Polymer Research: Jubilees — Beloved Occasions for Cultural Piety. Angew Chem Int Ed 43: 1064–1076CrossRefGoogle Scholar
  19. 19.
    Gros L, Ringsdorf H, Schupp H (1981) Polymerie antitumour agents on a molecular and cellular level. Angew Chemie Int Ed Eng 20: 301–323CrossRefGoogle Scholar
  20. 20.
    Regelson W, Parker G (1986) The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest 4: 29–42CrossRefPubMedGoogle Scholar
  21. 21.
    Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Polymer Sci Polymer Symp 51:135–153CrossRefGoogle Scholar
  22. 22.
    Lee CC, MacKay JA, Fréchet JMJ, Szoka FC (2005) Designing dendrimers for biological applications. Nature Biotechnol 23: 1517–1526CrossRefGoogle Scholar
  23. 23.
    Ng EWM, Shima DT, Calias P, Cunningham Jr ET, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Rev Drug Discov 5:125–132CrossRefGoogle Scholar
  24. 24.
    Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, Deventer SV, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005) Natalizumab induction and maintenance therapy for Crohn’s disease N Engl J Med 353(18): 1912–1935CrossRefPubMedGoogle Scholar
  25. 25.
    Eldar-Lissai A, Cosier LE, Culakova E, Lyman GH (2008) Economic analysis of prophylactic peg-filgrastim in adult cancer patients receiving chemotherapy. Value Health 11: 172–179CrossRefPubMedGoogle Scholar
  26. 26.
    Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y (2007) A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg 70: 177–187PubMedGoogle Scholar
  27. 27.
    Eaton M (2007) Nanomedicine: industry-wise research, Nature Mater 6: 251–253CrossRefGoogle Scholar
  28. 28.
    Gaspar R (2007) Regulatory issues surrounding nanomedicines: setting the scene for the nextgeneration of nanopharmaceuticals. Nanomedicine 2: 143–147CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Ruth Duncan
    • 1
  • Francesco M. Veronese
    • 2
  1. 1.Centre for Polymer TherapeuticsWelsh School of PharmacyCardiffUK
  2. 2.Department of Pharmaceutical SciencesUniversity of PaduaPaduaItaly

Personalised recommendations